| Literature DB >> 28187085 |
Lenine J P Liebenberg1, Lindi Masson, Kelly B Arnold, Lyle R Mckinnon, Lise Werner, Elizabeth Proctor, Derseree Archary, Leila E Mansoor, Douglas A Lauffenburger, Quarraisha Abdool Karim, Salim S Abdool Karim, Jo-Ann S Passmore.
Abstract
BACKGROUND: Mucosal and systemic immune mediators have been independently associated with HIV acquisition risk, but the relationship between compartments remains unclear.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28187085 PMCID: PMC5305292 DOI: 10.1097/QAI.0000000000001218
Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN: 1525-4135 Impact factor: 3.731
Demographic and Behavioral Characteristics of Study Participants
Relationship Between Systemic Cytokines and Risk of HIV Infection in Women From the CAPRISA 004 Trial
FIGURE 1.Mucosal–plasma chemokine gradients in women who remained uninfected (controls; n = 50) and in HIV- women who subsequently acquired HIV (cases; n = 57) during the CAPRISA 004 trial. Intercompartmental cytokine gradients were determined by quantifying the difference between standardized cytokine concentrations of the female genital tract and blood plasma for each participant. Four of the 5 gradients associated with HIV outcome in multivariate analysis are depicted here: (A) IP-10, (B) MIP-1β, (C) IL-8, and (D) monocyte chemotactic protein-1 (MCP-1). “Positive” gradients are indicative of higher relative levels in the genital tract compared with the blood.
Relationship Between Mucosa–Plasma Cytokine Gradients and Risk of HIV Infection in Women From the CAPRISA 004 Trial
FIGURE 2.Decision tree analyses to identify the most influential combinations of genital and plasma, cytokine measurements associated with HIV outcome. Cytokine concentrations determined in cases (n = 57) and controls (n = 50) were modeled to include (A) the concentrations of all 12 cytokines in genital and plasma specimens, (B) mucosal-Plasma gradients, (C) all 12 genital cytokines alone, or (D) all 12 plasma cytokines. Comparison of the (E) calibration and (F) cross-Validation errors for decision trees generated using either plasma, CVL, combined CVL and plasma, or cytokine gradients, respectively.